{"organizations": [], "uuid": "d4669b061bd1f67e4b23398859a162d1cb5d0053", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shionogi-says-viiv-healthcare-file/brief-shionogi-says-viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-over-bictegravir-idUSL4N1PY2Y9", "country": "US", "domain_rank": 408, "title": "BRIEF-Shionogi says ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.368, "site_type": "news", "published": "2018-02-08T15:06:00.000+02:00", "replies_count": 0, "uuid": "d4669b061bd1f67e4b23398859a162d1cb5d0053"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shionogi-says-viiv-healthcare-file/brief-shionogi-says-viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-over-bictegravir-idUSL4N1PY2Y9", "ord_in_thread": 0, "title": "BRIEF-Shionogi says ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir", "locations": [], "entities": {"persons": [{"name": "brief-shionogi", "sentiment": "negative"}], "locations": [{"name": "canada", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}, {"name": "toronto", "sentiment": "none"}], "organizations": [{"name": "gilead sciences", "sentiment": "negative"}, {"name": "reuters) - shionogi & co ltd", "sentiment": "neutral"}, {"name": "pfizer inc.", "sentiment": "none"}, {"name": "u.s. district court for the district of delaware", "sentiment": "none"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "shionogi limited", "sentiment": "none"}, {"name": "canadian federal court", "sentiment": "none"}, {"name": "gsk", "sentiment": "none"}, {"name": "gilead sciences inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Shionogi & Co Ltd\n* Says it announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada\n* The United States case is filed in the U.S. District Court for the District of Delaware and the patent is U.S patent No. 8,129,385\n* The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No. 2,606,282.\nSource text in Japanese: goo.gl/A6JmYz\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/A6JmYz"], "published": "2018-02-08T15:06:00.000+02:00", "crawled": "2018-02-09T16:40:52.025+02:00", "highlightTitle": ""}